Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
2024年7月9日 - 7:45PM
ビジネスワイヤ(英語)
Pfizer Inc. (NYSE: PFE) today announced that the company is
launching the process to identify a successor for Dr. Mikael
Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer
Research & Development, who will depart the company after a
more than 15-year stellar career. This process is expected to last
several months, probably through early next year. Pfizer will
initiate an external search for a new Chief Scientific Officer, and
Dr. Dolsten will assist in this search and continue to serve in his
current position until his successor is in place and any necessary
transition is complete.
“After more than 15 years as the architect of Pfizer’s
exceptional scientific and research and development resurgence,
Mikael and I recently discussed starting the process to look for
his successor,” said Albert Bourla, Chairman and Chief Executive
Officer, Pfizer. “I want to thank Mikael for his incredible
contributions, not only to Pfizer and the scientific community, but
to the millions of patients he has impacted over the years. Mikael
is a distinguished scientist, physician, and leader, and his work
will undoubtedly leave an important stamp on the legacy of this
175-year-old company.”
During his tenure at Pfizer, the company has received so far,
more than 35 drug and vaccines approvals of which more than half
were new molecular entities. These include products ranging from
therapies for inflammatory diseases, cardiovascular, stroke
prevention, hemophilia and cancer, to Pfizer’s vaccines for RSV,
pneumococcal and meningococcal diseases, with his most significant
accomplishments being the development and subsequent approval of
the company’s COVID-19 vaccine and oral therapeutic.
“Leading research and development at Pfizer has been a journey
of a lifetime,” said Mikael Dolsten, Chief Scientific Officer and
President, Pfizer Research & Development. “I am incredibly
proud of all that we have accomplished in creating a world-class
R&D organization with amazing talent, industry-leading
scientific platforms, and a first-in-class pipeline and portfolio.
I look forward to working closely with Albert to find a new leader
who can build on our success and bring even more breakthroughs to
patients in need.”
Dr. Dolsten joined Pfizer as part of the Wyeth acquisition in
2009 when he was named President of Worldwide Research and
Development with responsibility to lead all of Pfizer’s research as
well as development of all compounds through Phase 2. At Wyeth, he
was President of Wyeth Research, where he led scientists involved
in all research and development and medical activities across the
U.S., Europe and Asia. Prior to this, he served as Executive Vice
President and Head of Worldwide Research for Boehringer Ingelheim
from 2003 to 2008, and Global Vice President of Research and
Development at AstraZeneca from 1997 to 2003.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
175 years, we have worked to make a difference for all who rely on
us. We routinely post information that may be important to
investors on our website at www.Pfizer.com. In addition, to learn
more, please visit us on www.Pfizer.com and follow us on X at
@Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of July 9, 2024. The Company assumes no obligation to
update forward-looking statements contained in this release as the
result of new information or future events or developments.
This release contains forward-looking statements about Pfizer’s
process to identify a new Chief Scientific Officer and Pfizer’s
research and development pipeline and portfolio, including their
potential benefits, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet
anticipated clinical endpoints, commencement and/or completion
dates for our clinical trials, regulatory submission dates,
regulatory approval dates and/or launch dates, as well as the
possibility of unfavorable new clinical data and further analyses
of existing clinical data; the risk that clinical trial data are
subject to differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from our clinical studies; whether and
when any drug applications, biologics license applications and/or
emergency use authorization applications may be filed in any
jurisdictions for any potential indication for Pfizer’s product
candidates; whether and when any such applications that may be
pending or filed for any of Pfizer’s product candidates may be
approved by regulatory authorities, which will depend on myriad
factors, including making a determination as to whether the
product's benefits outweigh its known risks and determination of
the product's efficacy and, if approved, whether any such product
candidates will be commercially successful; decisions by regulatory
authorities impacting labeling, manufacturing processes, safety
and/or other matters that could affect the availability or
commercial potential of Pfizer’s product candidates, including
development of products or therapies by other companies;
manufacturing capabilities or capacity; uncertainties regarding the
ability to obtain recommendations from vaccine technical committees
and other public health authorities and uncertainties regarding the
commercial impact of any such recommendations; the uncertainties
inherent in business and financial planning, including, without
limitation, risks related to Pfizer’s business and prospects,
adverse developments in Pfizer’s markets, or adverse developments
in the U.S. or global capital markets, credit markets, regulatory
environment or economies generally; the impact of COVID-19 on our
business, operations and financial results; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
Category: Corporate, Leadership
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709792921/en/
Media Contact: PfizerMediaRelations@Pfizer.com +1 (212)
733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2024 まで 10 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 10 2023 まで 10 2024